FDA 483 - Matthew Brimberry, MD - January 30, 2026

An FDA inspection of Matthew Brimberry, MD, a clinical investigator in Austin, TX, revealed a significant issue with the conduct of an investigation. Specifically, a medication error was not reported to the sponsor within the required timeframe, and a subject was randomized into a study without documented confirmation of eligibility criteria, both deviations from the study protocol.